LON:DOCS - Dr. Martens Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 6,525
  • Forecasted Upside: 1,449.88 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 421
▲ +9 (2.18%)

This chart shows the closing price for DOCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dr. Martens Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOCS

Analyst Price Target is GBX 6,525
▲ +1,449.88% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Dr. Martens in the last 3 months. The average price target is GBX 6,525, with a high forecast of £125 and a low forecast of GBX 550. The average price target represents a 1,449.88% upside from the last price of GBX 421.

This chart shows the closing price for DOCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Dr. Martens.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/18/2021BarclaysReiterated RatingOverweight£125
3/11/2021Royal Bank of CanadaReiterated RatingOutperformGBX 550
(Data available from 6/22/2016 forward)
Dr. Martens logo
Dr. Martens Limited engages in the manufacture and sale of footwear in the United Kingdom and internationally. Its product segments include originals, fusion, kids and casual, and a complementary range of accessories. The company offers its products under Dr. Martens brand name. It operates Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens Limited was founded in 1960 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 421
Low: 397.60
High: 428

50 Day Range

MA: GBX 475.33
Low: 412
High: 505.82

52 Week Range

Now: GBX 421
Low: 395.80
High: 521.60

Volume

1,111,050 shs

Average Volume

1,500,869 shs

Market Capitalization

£4.21 billion

P/E Ratio

116.94

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dr. Martens?

The following Wall Street sell-side analysts have issued research reports on Dr. Martens in the last twelve months: Barclays PLC, and Royal Bank of Canada.
View the latest analyst ratings for DOCS.

What is the current price target for Dr. Martens?

2 Wall Street analysts have set twelve-month price targets for Dr. Martens in the last year. Their average twelve-month price target is GBX 6,525, suggesting a possible upside of 1,449.9%. Barclays PLC has the highest price target set, predicting DOCS will reach £125 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 550 for Dr. Martens in the next year.
View the latest price targets for DOCS.

What is the current consensus analyst rating for Dr. Martens?

Dr. Martens currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DOCS will outperform the market and that investors should add to their positions of Dr. Martens.
View the latest ratings for DOCS.

What other companies compete with Dr. Martens?

Other companies that are similar to Dr. Martens include Puma, Samsonite International, Pittards, adidas, adidas, ASICS, Dr. Martens, Geox, Kering, Puma, Puma, TOD'S, XPD Soccer Gear Group and Yue Yuen Industrial.